Lifeward Ltd. (LFWD) Spending and interest coverage
- R&D / revenue · 12 months: Value 756.65%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 64.41%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 756.65% | Research and development expense / revenue. Period ending 2026-06-30. $9.16M ÷ $1.21M × 100 ≈ 756.65% |
| Stock-based compensation / revenue · 12 months | 64.41% | Share-based compensation / revenue. Period ending 2026-06-30. $780.00K ÷ $1.21M × 100 ≈ 64.41% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 9.16M USD | Research and Development Expense |
| Revenue | 1.21M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 780.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -22.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.16M | $1.21M | $780.00K | $-22.75M | (m) | 756.65% | 64.41% | (m) | (m) |
| 2026-03-31 | $8.18M | $1.34M | $700.00K | $-25.16M | (m) | 608.79% | 52.12% | (m) | (m) |
| 2025-12-31 | $3.25M | $1.40M | $743.00K | $-19.67M | (m) | 232.07% | 53.07% | (m) | (m) |
| 2025-09-30 | $3.54M | $1.30M | $810.00K | $-29.78M | (m) | 272.08% | 62.31% | (m) | (m) |
| 2025-06-30 | $3.81M | $1.61M | $926.00K | $-29.82M | (m) | 236.60% | 57.44% | (m) | (m) |
| 2025-03-31 | $4.25M | $1.71M | $1.12M | $-27.70M | (m) | 248.51% | 65.46% | (m) | (m) |
| 2024-12-31 | $4.63M | $1.70M | $1.28M | $-29.35M | (m) | 272.06% | 75.35% | (m) | (m) |
| 2024-09-30 | $4.81M | $1.75M | $1.42M | $-20.26M | (m) | 275.76% | 81.38% | (m) | (m) |
| 2024-06-30 | $5.08M | $1.22M | $1.46M | $-25.02M | (m) | 416.75% | 120.11% | (m) | (m) |
| 2024-03-31 | $4.69M | $796.00K | $1.41M | $-25.74M | (m) | 588.82% | 176.51% | (m) | (m) |
| 2023-12-31 | $4.15M | $435.00K | $1.33M | $-23.61M | (m) | 953.56% | 305.29% | (m) | (m) |
| 2023-09-30 | $3.93M | $362.00K | $1.30M | $-22.48M | (m) | 1086.46% | 359.67% | (m) | (m) |
| 2023-06-30 | $3.74M | $357.00K | $1.29M | $-19.97M | (m) | 1046.50% | 361.06% | (m) | (m) |
| 2023-03-31 | $3.88M | $357.00K | $1.14M | $-19.19M | (m) | 1085.71% | 320.45% | (m) | (m) |
| 2022-12-31 | $4.03M | $352.00K | $993.00K | $-19.10M | (m) | 1145.17% | 282.10% | (m) | (m) |
| 2022-09-30 | $3.62M | $341.00K | $880.00K | $-17.93M | (m) | 1062.76% | 258.06% | (m) | (m) |
| 2022-06-30 | $3.20M | $339.00K | $791.00K | $-15.16M | (m) | 943.07% | 233.33% | (m) | (m) |
| 2022-03-31 | $3.05M | $364.00K | $818.00K | $-13.92M | (m) | 838.19% | 224.73% | (m) | (m) |
| 2021-12-31 | $2.94M | $432.00K | $833.00K | $-12.65M | (m) | 680.32% | 192.82% | (m) | (m) |
| 2021-09-30 | $3.01M | $-2.47M | $804.00K | $-11.61M | (m) | -121.54% | -32.50% | (m) | (m) |
| 2021-06-30 | $3.13M | $-1.80M | $805.00K | $-12.01M | (m) | -173.13% | -44.60% | (m) | (m) |
| 2021-03-31 | $3.27M | $-239.00K | $718.00K | $-11.42M | (m) | -1367.78% | -300.42% | (m) | (m) |
| 2020-12-31 | $3.46M | $330.00K | $749.00K | $-12.00M | (m) | 1048.18% | 226.97% | (m) | (m) |
| 2020-09-30 | $3.75M | $4.36M | $783.00K | $-12.43M | (m) | 86.11% | 17.98% | (m) | (m) |
| 2020-06-30 | $4.01M | $4.84M | $787.00K | $-12.39M | (m) | 82.86% | 16.25% | (m) | (m) |
| 2020-03-31 | $4.92M | $4.05M | $988.00K | $-14.07M | (m) | 121.40% | 24.38% | (m) | (m) |
| 2019-12-31 | $5.35M | $4.87M | $1.11M | $-14.05M | (m) | 109.75% | 22.74% | (m) | (m) |
| 2019-09-30 | $6.00M | $5.27M | $1.29M | $-14.81M | (m) | 113.75% | 24.53% | (m) | (m) |
| 2019-06-30 | $6.58M | $5.65M | $1.58M | $-15.91M | (m) | 116.29% | 27.94% | (m) | (m) |
| 2019-03-31 | $6.61M | $6.55M | $2.29M | $-16.95M | (m) | 100.99% | 34.96% | (m) | (m) |
| 2018-12-31 | $7.35M | $6.54M | $2.77M | $-19.21M | (m) | 112.28% | 42.26% | (m) | (m) |
| 2018-09-30 | $7.25M | $6.48M | $3.40M | $-20.86M | (m) | 111.93% | 52.45% | (m) | (m) |
| 2018-06-30 | $7.28M | $6.60M | $3.77M | $-22.09M | (m) | 110.29% | 57.23% | (m) | (m) |
| 2018-03-31 | $6.76M | $6.83M | $3.60M | $-22.18M | (m) | 98.98% | 52.67% | (m) | (m) |
| 2017-12-31 | $6.04M | $7.75M | $3.65M | $-21.99M | (m) | 77.93% | 47.13% | (m) | (m) |
| 2017-09-30 | $6.72M | $7.83M | $3.54M | $-24.41M | (m) | 85.89% | 45.18% | (m) | (m) |
| 2017-06-30 | $7.07M | $7.50M | $3.55M | $-26.46M | (m) | 94.36% | 47.39% | (m) | (m) |
| 2017-03-31 | $8.76M | $6.31M | $3.53M | $-29.68M | (m) | 138.94% | 56.00% | (m) | (m) |
| 2016-12-31 | $9.03M | $5.87M | $3.40M | $-30.44M | (m) | 153.83% | 57.90% | (m) | (m) |
| 2016-09-30 | $8.42M | $5.61M | $3.12M | $-29.91M | (m) | 150.05% | 55.56% | (m) | (m) |
| 2016-06-30 | $7.72M | $5.38M | $2.72M | $-28.81M | (m) | 143.50% | 50.51% | (m) | (m) |
| 2016-03-31 | $6.09M | $5.17M | $2.48M | $-26.07M | (m) | 117.85% | 47.87% | (m) | (m) |
| 2015-12-31 | $5.94M | $3.75M | $2.35M | $-25.17M | (m) | 158.49% | 62.60% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $8.56M | $3.95M | $5.18M | $-19.93M | (m) | 216.73% | 131.08% | (m) | (m) |
| 2013-12-31 | $2.46M | $1.59M | $215.00K | $-8.74M | (m) | 155.10% | 13.54% | (m) | (m) |
| 2012-12-31 | $1.76M | $972.00K | $113.00K | $-5.76M | (m) | 180.76% | 11.63% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENvue Medical, Inc. (FEED) | United States | $0.011B | |
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| Bone Biologics Corp (BBLG) | United States | $0.001B | |
| LogicMark, Inc. (LGMK) | United States | $0.000B | |
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| NutriBand Inc. (NTRB) | United States | $0.109B |